[PHP62] Biosimilar Substitution Policies: An Overview

[PHP62] Biosimilar Substitution Policies: An Overview

2015 Value in Health

Mendoza, C. | Ionescu, D. | Radière, G. | Rémuzat, C. | Young, K. E. | Toumi, M. | Volume: 18, Issue: 7, Pages: A525,

Substitution has been implemented for generics in most markets and very often resulted in high uptake correlated with fast and strong price erosion. Although biosimilars and generics are different, the low biosimilar penetration in most of Europe prompted some countries to discuss the implementation of substitution for biosimilars as an initiative to quickly reduce healthcare spending by boosting their uptake. The objective of this study was to identify initiatives undertaken worldwide with regards to biosimilar substitution and their potential implications.

https://www.doi.org/10.1016/j.jval.2015.09.1616